Imago BioSciences, Inc.
Period
FY 2021
Revenue
—
Net Income
$-42.31M
Total Assets
$224.79M
Equity
$214.69M
Shares Out
33.82M
Op. Cash Flow
$-39.76M
Business
Imago BioSciences, Inc. is a former operating company in Pharmaceutical Preparations, incorporated in Delaware. Securities are no longer actively traded on a major U.S. exchange.
Auto-generated from company profile
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2021 2021-12-31 | FY 2020 2020-12-31 |
|---|---|---|---|
| Research and development | 32 | 15 | |
| General and administrative | 10 | 3 | |
| Total operating expenses | 43 | 18 | |
| Loss from operations | −43 | −18 | |
| Interest income | 314,000 | 48,000 | |
| Change in fair value of convertible preferred stock tranche liability | — | 214,000 | |
| Other expense, net | −99,000 | −20,000 | |
| Total other income, net | 215,000 | 242,000 | |
| Loss before income tax expense | −42 | −18 | |
| Income tax expense | −2,000 | −3,000 | |
| Net loss | −42 | −18 | |
| Net loss per share, basic and diluted | −2.7 | −17.49 | |
| Weighted-average shares used in computing net loss per share, basic and diluted | 16 | 1 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2021 2021-12-31 | FY 2020 2020-12-31 | FY 2019 2019-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | 11 | 19 | — | |
| Short-term investments | 206 | 57 | — | |
| Prepaid expenses and other current assets | 4 | 1 | — | |
| Total current assets | 221 | 78 | — | |
| Property and equipment, net | 2,000 | 8,000 | — | |
| Long-term investments | — | 20 | — | |
| Other long-term assets | 3 | 1 | — | |
| Total assets | 225 | 99 | — | |
| Accounts payable | 3 | 1 | — | |
| Accrued and other current liabilities | 7 | 4 | — | |
| Total current liabilities | 10 | 5 | — | |
| Commitments and contingencies (Note 6) | — | — | — | |
| Convertible preferred stock, $0.0001 par value; 0 and 180,059,639 shares authorized, as of December 31, 2021 and 2020, respectively; 0 and 21,435,632 issued and outstanding as of December 31, 2021 and 2020, respectively; aggregate liquidation preference of $0 as of December 31, 2021 | 0 | 163 | — | |
| Preferred stock, $0.0001 par value; 10,000,000 and 0 shares authorized as of December 31, 2021 and 2020, respectively; 0 issued and outstanding as of December 31, 2021 and 2020, respectively | 0 | 0 | — | |
| Common stock, $0.0001 par value; 300,000,000 and 228,300,000 shares authorized as of December 31, 2021 and 2020, respectively; 33,531,743 and 1,030,023 shares issued and outstanding as of December 31, 2021 and 2020, respectively | 3,000 | 0 | — | |
| Additional paid-in capital | 327 | 2 | — | |
| Accumulated other comprehensive income (loss) | −43,000 | −3,000 | — | |
| Accumulated deficit | −113 | −70 | — | |
| Total stockholders' equity (deficit) | 215 | −69 | −51 | |
| Total liabilities, convertible preferred stock and stockholders' equity (deficit) | 225 | 99 | — |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2021 2021-12-31 | FY 2020 2020-12-31 |
|---|---|---|---|
| Net loss | −42 | −18 | |
| Amortization of premium and discounts on available-for-sale investments | 109,000 | 6,000 | |
| Depreciation and amortization | 6,000 | 1,000 | |
| Stock-based compensation | 2 | 426,000 | |
| Prepaid expenses and other current assets | −3 | −393,000 | |
| Other long-term assets | −2 | −1 | |
| Accounts payable | 2 | 8,000 | |
| Accrued expenses and other current liabilities | 3 | 2 | |
| Net cash used in operating activities | −40 | −17 | |
| Purchases of property and equipment | — | −9,000 | |
| Purchases of available-for-sale investments | −208 | −81 | |
| Proceeds from maturities of available-for-sale investments | 79 | 7 | |
| Net cash used in investing activities | −129 | −74 | |
| Payments of offering costs related to initial public offering | −3 | — | |
| Proceeds from exercise of stock options | 506,000 | 29,000 | |
| Net cash provided by financing activities | 161 | 106 | |
| Net (decrease) increase in cash and cash equivalents | −8 | 14 | |
| Cash paid for taxes | 74,000 | 14,000 | |
| Settlement of Convertible preferred stock liability in connection with the issuance of Series B convertible preferred stock | — | 2 | |
| Conversion of convertible preferred stock to common stock upon initial public offering | 163 | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is Imago BioSciences, Inc.'s CIK number?
Imago BioSciences, Inc.'s SEC CIK number is 0001623715 (1623715). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Imago BioSciences, Inc.'s SEC filings?
All of Imago BioSciences, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.